Get notified of page updates
Enroll in Research > Research Search & Enroll Tool > ATR Inhibitor Plus Niraparib Study in Advanced Solid Tumors and Ovarian Cancer
Glossary on
off
Printer Friendly Page ATR Inhibitor Plus Niraparib Study in Advanced Solid Tumors and Ovarian Cancer

ATR Inhibitor Plus Niraparib Study in Advanced Solid Tumors and Ovarian Cancer

Clinicaltrials.gov identifier:
NCT04267939


Advanced ovarian cancer or other solid tumors

Study Contact Information:

For additional information, contact: Bayer Clinical Trials by phone: 1-888-842-2937 or by email 


ATR Inhibitor BAY 1895344 Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer

About the Study

This study will look at how well how people with advanced ovarian, or primary peritoneal cancer or other respond to treatment with the BAY1895344 in combination with the niraparib. This study is open to participants who have had their ovarian cancer progress while on a

This study is no longer enrolling people.

This Study is Open To:

This study is no longer enrolling people.

 

This Study is Not Open To:

This study is no longer enrolling people.